US
CA
NZ
UK
AU
IND
Last update at 2025-05-22T16:53:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Fri 09 May 25, 08:05 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -95.63900M | -54.85300M | -19.95500M | -5.16100M | -5.09700M |
| Minority interest | - | - | - | - | - |
| Net income | -87.26200M | -54.37400M | -18.63400M | -4.70200M | -5.09700M |
| Selling general administrative | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.84M | 0.48M | - | - | - |
| Ebit | -104.01600M | -64.02200M | -19.99500M | -5.44900M | -5.00900M |
| Ebitda | -78.85500M | -55.18700M | -18.67400M | -4.74400M | -5.08800M |
| Depreciation and amortization | 25.16M | 8.84M | 1.32M | 0.70M | -0.07900M |
| Non operating income net other | 3.22M | 0.33M | -1.28100M | - | - |
| Operating income | -104.01600M | -64.02200M | -19.99500M | -5.44900M | -5.00900M |
| Other operating expenses | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest expense | 24.32M | 0.00300M | 0.37M | 0.35M | 0.00900M |
| Tax provision | - | - | - | - | - |
| Interest income | - | 0.34M | 0.12M | 0.05M | 0.09M |
| Net interest income | - | 0.33M | -0.24300M | -0.29500M | 0.08M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | -10.00000M | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -8.37700M | -0.47900M | -1.32100M | -0.45900M | -0.07600M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 8.38M | 9.17M | 0.04M | 0.29M | -0.16400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -100.80000M | -54.85300M | -19.95500M | -5.16100M | -5.09700M |
| Net income applicable to common shares | -95.63900M | -54.85300M | -19.98800M | -5.16100M | -5.09700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 160.25M | 258.15M | 332.01M | 279.56M | 2.19M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 5.68M | 7.19M | 7.04M | 7.66M | 0.10M |
| Total liab | 30.06M | 23.02M | 10.92M | 5.28M | 21.91M |
| Total stockholder equity | 130.19M | 235.14M | 321.08M | 274.28M | -19.72300M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 28.71M | 18.60M | 8.44M | 3.12M | 0.85M |
| Common stock | 0.00400M | 0.00400M | 0.00400M | 0.00300M | 0.00300M |
| Capital stock | 0.00400M | 0.00400M | 0.00400M | 0.00300M | 0.00000M |
| Retained earnings | -309.20600M | -191.53400M | -95.89500M | -41.04200M | -21.08700M |
| Other liab | - | - | - | - | 2.04M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.47M | 5.27M | 84.58M | 0.03M |
| Cash | 90.58M | 95.97M | 110.54M | 60.62M | 2.06M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 28.84M | 21.43M | 9.29M | 4.41M | 1.27M |
| Current deferred revenue | -0.36800M | - | - | - | - |
| Net debt | -88.99900M | -94.05500M | -108.61700M | -59.62500M | -0.50300M |
| Short term debt | 0.37M | 0.33M | 0.29M | 0.12M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.58M | 1.91M | 1.92M | 1.00M | 1.55M |
| Other stockholder equity | 439.39M | 428.62M | 417.36M | 35.73M | 1.36M |
| Property plant equipment | - | 4.05M | 3.76M | 3.58M | - |
| Total current assets | 154.73M | 207.53M | 260.80M | 192.34M | 2.16M |
| Long term investments | 0.00000M | 44.83M | 65.94M | 83.51M | - |
| Net tangible assets | - | 235.14M | 321.08M | 274.28M | -19.72300M |
| Short term investments | 56.84M | 104.38M | 143.22M | 124.06M | 0.00000M |
| Net receivables | 1.63M | 1.23M | 2.34M | 1.30M | 0.00700M |
| Long term debt | - | - | - | - | 1.55M |
| Inventory | - | -1.22700M | -2.33600M | -1.30000M | - |
| Accounts payable | 0.13M | 2.50M | 0.57M | 1.16M | 0.42M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.34900M | -1.95600M | -0.38800M | 0.03M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00400M | 0.00400M | 0.00300M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -191.53400M | -95.89500M | -41.04200M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.45M | 0.47M | 0.06M | 0.13M | 0.03M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5.52M | 50.62M | 71.21M | 87.23M | 0.03M |
| Capital lease obligations | 1.58M | 1.91M | 1.92M | 1.00M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 58.80M | -2.50600M | -210.06800M | 1.50M | 2.00M |
| Change to liabilities | 2.10M | 5.15M | 1.10M | 0.70M | 0.29M |
| Total cashflows from investing activities | 57.66M | -4.07900M | -210.06800M | 1.51M | 2.01M |
| Net borrowings | - | - | 1.66M | 0.87M | 1.27M |
| Total cash from financing activities | 0.65M | 97.09M | 292.75M | 0.95M | 1.46M |
| Change to operating activities | 8.73M | 2.05M | 0.06M | 0.06M | -0.04600M |
| Net income | -95.63900M | -54.85300M | -19.95500M | -5.16100M | -5.09700M |
| Change in cash | -14.15100M | 49.91M | 58.57M | -1.26100M | -1.01200M |
| Begin period cash flow | 110.54M | 60.62M | 2.06M | 3.32M | 4.33M |
| End period cash flow | 96.39M | 110.54M | 60.62M | 2.06M | 3.32M |
| Total cash from operating activities | -72.46900M | -43.09800M | -24.11300M | -3.71300M | -4.48300M |
| Issuance of capital stock | 0.00000M | 96.76M | 290.44M | 0.00000M | 0.10M |
| Depreciation | 0.84M | 0.48M | 0.25M | 0.00200M | 0.00200M |
| Other cashflows from investing activities | - | - | 0.04M | 0.00600M | 0.00700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 1.11M | -1.03600M | -7.61000M | -0.02300M | -0.02300M |
| Sale purchase of stock | - | 96.76M | 208.52M | - | - |
| Other cashflows from financing activities | 57.66M | 0.33M | 84.23M | 0.95M | 1.46M |
| Change to netincome | 10.61M | 4.62M | 2.00M | 0.51M | 0.36M |
| Capital expenditures | 1.14M | 1.57M | 2.32M | 2.32M | 2.32M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | 10.04M | 1.01M | -7.94100M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -14.15100M | 49.91M | 58.57M | - | - |
| Change in working capital | 11.94M | 6.16M | -6.44500M | 0.68M | 0.24M |
| Stock based compensation | 10.61M | 4.62M | 0.63M | 0.25M | 0.20M |
| Other non cash items | -0.21900M | 0.49M | 1.65M | 0.52M | 0.17M |
| Free cash flow | -73.61000M | -44.67100M | -26.43300M | -3.71300M | -4.48300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| ATHA Athira Pharma Inc |
-0.001 0.37% | 0.27 | - | - | - | 0.43 | 1.31 | |
| NVO Novo Nordisk A/S |
-0.155 0.23% | 68.05 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.95 1.40% | 68.95 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.41 1.01% | 430.91 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-10.3 1.70% | 594.32 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
18706 North Creek Parkway, Bothell, WA, United States, 98011
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark J. Litton M.B.A., MBA, Ph.D. | Pres, CEO & Director | 1968 |
| Ms. Rachel P. Lenington M.B.A. | Chief Operating Officer | NA |
| Mr. Mark F. Worthington J.D. | Gen. Counsel & Corp. Sec. | NA |
| Ms. Glenna K. Mileson | Chief Financial Officer | 1959 |
| Mr. Robert Renninger | Director of Accounting & Reporting | NA |
| Ms. Julie Rathbun | Head of Investor Relations | NA |
| Dr. Kevin Church Ph.D. | Exec. VP of Research | 1985 |
| Dr. Mark J. Litton M.B.A., Ph.D. | President, CEO & Director | 1968 |
| Ms. Rachel P. Lenington M.B.A. | Chief Development Officer & COO | 1973 |
| Mr. Andrew W. Gengos | CFO & Chief Business Officer | 1964 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...